Last reviewed · How we verify

NCT03564171

Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer

Completed Phase 2, PHASE3 Last updated 12 April 2023
What this trial tests

Phase 2, PHASE3 trial testing Prehabilitation in Breast Cancer in 63 participants. Completed in 31 March 2023.

Timeline
18 July 2018
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorSunnybrook Health Sciences Centre
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment63
Start date18 July 2018
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

Adults 18 to 80, female only, with Breast Cancer or Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Prehabilitation

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03564171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing